Benzinga | Aug 9, 2021 04:06PM EDT

AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer

* AstraZeneca plc (NASDAQ:AZN) and Daiichi Sankyo Co Ltd (OTC:DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu.

* The trial reached its primary endpoint in a study including HER2-positive metastatic breast cancer patients who had previously been treated with one prior line of HER2-based therapy.

* Enhertu demonstrated superiority in progression-free survival (PFS) over Roche Holdings AG's (OTC:RHHBY) Kadcyla (trastuzumab emtansine) and chemo.

* Complete data aren't available yet, but Daiichi Sankyo noted the trial had been recommended for unblinding by the Independent Data Monitoring Committee (IDMC) after reaching this interim analysis.

* The companies also said that while overall survival data showed a "strong trend" toward improvement over the control, the OS data haven't matured enough to conclude anything.

* Price Action: DSKYF shares are down 2.65% at $17.61, while AZN stock is up 0.43% at $56.60 during the market session on the last check Monday.